Skip to content
lifestyle.friendhood.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Ipsen Pharma
Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
July 30, 2026
Ipsen nominates Catherine Bradley to its Board of Directors as independent Director
July 29, 2026
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline
July 22, 2026
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
July 9, 2026
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
July 1, 2026
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
April 23, 2026
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
April 22, 2026
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
March 18, 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America
March 12, 2026
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
March 9, 2026
1
2
Next Page
→